Marius TrÃ¸seid

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1329149/publications.pdf

Version: 2024-02-01

67 papers	2,730 citations	218677 26 h-index	197818 49 g-index
72 all docs	72 docs citations	72 times ranked	4433 citing authors

#	Article	IF	Citations
1	Microbiotaâ€dependent metabolite trimethylamineâ€Nâ€oxide is associated with disease severity and survival of patients with chronic heart failure. Journal of Internal Medicine, 2015, 277, 717-726.	6.0	359
2	The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. Gut, 2017, 66, 611-619.	12.1	308
3	The gut microbiome in coronary artery disease and heart failure: Current knowledge and future directions. EBioMedicine, 2020, 52, 102649.	6.1	209
4	Altered gut microbiota profile in common variable immunodeficiency associates with levels of lipopolysaccharide and markers of systemic immune activation. Mucosal Immunology, 2016, 9, 1455-1465.	6.0	130
5	The role of interleukin-18 in the metabolic syndrome. Cardiovascular Diabetology, 2010, 9, 11.	6.8	121
6	The Carnitine-butyrobetaine-trimethylamine-N-oxide pathway and its association with cardiovascular mortality in patients with carotid atherosclerosis. Atherosclerosis, 2016, 247, 64-69.	0.8	116
7	Increased Secondary/Primary Bile Acid Ratio in Chronic Heart Failure. Journal of Cardiac Failure, 2017, 23, 666-671.	1.7	98
8	Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19. Annals of Internal Medicine, 2021, 174, 1261-1269.	3.9	84
9	Elevated markers of gut leakage and inflammasome activation in COVIDâ€19 patients with cardiac involvement. Journal of Internal Medicine, 2021, 289, 523-531.	6.0	76
10	Altered Gut Microbial Metabolism of Essential Nutrients in Primary Sclerosing Cholangitis. Gastroenterology, 2021, 160, 1784-1798.e0.	1.3	69
11	Serum levels of interleukin-18 are reduced by diet and n-3 fatty acid intervention in elderly high-risk men. Metabolism: Clinical and Experimental, 2009, 58, 1543-1549.	3.4	65
12	Major Increase in Microbiota-Dependent Proatherogenic Metabolite TMAO One Year After Bariatric Surgery. Metabolic Syndrome and Related Disorders, 2016, 14, 197-201.	1.3	61
13	Low fibre intake is associated with gut microbiota alterations in chronic heart failure. ESC Heart Failure, 2020, 7, 456-466.	3.1	56
14	Circulating markers of gut barrier function associated with disease severity in primary sclerosing cholangitis. Liver International, 2019, 39, 371-381.	3.9	51
15	Fecal microbiota transplantation in systemic sclerosis: A double-blind, placebo-controlled randomized pilot trial. PLoS ONE, 2020, 15, e0232739.	2.5	47
16	Design of the GutHeartâ€"targeting gut microbiota to treat heart failureâ€"trial: a Phase II, randomized clinical trial. ESC Heart Failure, 2018, 5, 977-984.	3.1	39
17	Gut Microbiota-Dependent Trimethylamine N-Oxide Associates With Inflammation in Common Variable Immunodeficiency. Frontiers in Immunology, 2020, 11, 574500.	4.8	38
18	Respiratory dysfunction three months after severe COVIDâ€19 is associated with gut microbiota alterations. Journal of Internal Medicine, 2022, 291, 801-812.	6.0	38

#	Article	IF	Citations
19	Microbial Translocation and Cardiometabolic Risk Factors in HIV Infection. AIDS Research and Human Retroviruses, 2014, 30, 514-522.	1.1	37
20	Impact of Human Immunodeficiency Virusâ€"Related Gut Microbiota Alterations on Metabolic Comorbid Conditions. Clinical Infectious Diseases, 2020, 71, e359-e367.	5.8	36
21	Impact of HIV and Type 2 diabetes on Gut Microbiota Diversity, Tryptophan Catabolism and Endothelial Dysfunction. Scientific Reports, 2018, 8, 6725.	3.3	35
22	Markers of metabolic endotoxemia as related to metabolic syndrome in an elderly male population at high cardiovascular risk: a cross-sectional study. Diabetology and Metabolic Syndrome, 2018, 10, 59.	2.7	35
23	Rifaximin or Saccharomyces boulardii in heart failure with reduced ejection fraction: Results from the randomized GutHeart trial. EBioMedicine, 2021, 70, 103511.	6.1	34
24	The Effect of Exercise on Serum Levels of Interleukin-18 and Components of the Metabolic Syndrome. Metabolic Syndrome and Related Disorders, 2009, 7, 579-584.	1.3	33
25	Microbiota-dependent metabolite and cardiovascular disease marker trimethylamine-N-oxide (TMAO) is associated with monocyte activation but not platelet function in untreated HIV infection. BMC Infectious Diseases, 2017, 17, 445.	2.9	30
26	The microbial metabolite trimethylamine-N-oxide in association with inflammation and microbial dysregulation in three HIV cohorts at various disease stages. Aids, 2018, 32, 1589-1598.	2.2	26
27	Effect of Lactobacillus rhamnosus GG Supplementation on Intestinal Inflammation Assessed by PET/MRI Scans and Gut Microbiota Composition in HIV-Infected Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 450-457.	2.1	26
28	Persistent pulmonary pathology after COVID-19 is associated with high viral load, weak antibody response, and high levels of matrix metalloproteinase-9. Scientific Reports, 2021, 11, 23205.	3.3	26
29	High Mobility Group Box Protein-1 in HIV-1 Infection: Connecting Microbial Translocation, Cell Death and Immune Activation. Current HIV Research, 2011, 9, 6-10.	0.5	23
30	Soluble CD14 in cerebrospinal fluid is associated with markers of inflammation and axonal damage in untreated HIV-infected patients: a retrospective cross-sectional study. BMC Infectious Diseases, 2016, 16, 176.	2.9	23
31	Circulating levels of HMGB1 are correlated strongly with MD2 in HIV-infection: Possible implication for TLR4-signalling and chronic immune activation. Innate Immunity, 2013, 19, 290-297.	2.4	22
32	Activated dendritic cells and monocytes in HIV immunological nonresponders. Aids, 2019, 33, 1117-1129.	2.2	22
33	Rosuvastatin alters the genetic composition of the human gut microbiome. Scientific Reports, 2020, 10, 5397.	3.3	20
34	Synergistic Interferon-Alpha-Based Combinations for Treatment of SARS-CoV-2 and Other Viral Infections. Viruses, 2021, 13, 2489.	3.3	20
35	HIV-infected persons with type 2 diabetes show evidence of endothelial dysfunction and increased inflammation. BMC Infectious Diseases, 2017, 17, 234.	2.9	19
36	Probiotics to manage inflammation in HIV infection. Current Opinion in Infectious Diseases, 2020, 33, 34-43.	3.1	19

#	Article	IF	Citations
37	Effects of dietary intervention and n-3 PUFA supplementation on markers of gut-related inflammation and their association with cardiovascular events in a high-risk population. Atherosclerosis, 2019, 286, 53-59.	0.8	16
38	Human Immunodeficiency Virusâ€“Infected Immunological Nonresponders Have Colon-Restricted Gut Mucosal Immune Dysfunction. Journal of Infectious Diseases, 2022, 225, 661-674.	4.0	16
39	Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from DisCoVeRy and the EU-SolidAct EU response group. Clinical Microbiology and Infection, 2022, 28, 1-5.	6.0	15
40	Soluble Markers of Interleukin 1 Activation as Predictors of First-Time Myocardial Infarction in HIV-Infected Individuals. Journal of Infectious Diseases, 2019, 221, 506-509.	4.0	14
41	The carnitine-butyrobetaine-TMAO pathway after cardiac transplant: Impact on cardiac allograft vasculopathy and acute rejection. Journal of Heart and Lung Transplantation, 2019, 38, 1097-1103.	0.6	13
42	Microbial translocation revisited. Aids, 2019, 33, 645-653.	2.2	11
43	Immune activation and HIV-specific T cell responses are modulated by a cyclooxygenase-2 inhibitor in untreated HIV-infected individuals: An exploratory clinical trial. PLoS ONE, 2017, 12, e0176527.	2.5	10
44	Independent Association of Interleukin 6 With Low Dynamic Lung Function and Airflow Limitation in Well-Treated People With Human Immunodeficiency Virus. Journal of Infectious Diseases, 2021, 223, 1690-1698.	4.0	10
45	Monocyte count and soluble markers of monocyte activation in people living with HIV and uninfected controls. BMC Infectious Diseases, 2022, 22, 451.	2.9	10
46	Tâ€cell homeostasis in chronic HCVâ€infected patients treated with interferon and ribavirin or an interferonâ€free regimen. Apmis, 2015, 123, 903-911.	2.0	9
47	Bariatric surgery reduces fasting total fatty acids and increases n-3 polyunsaturated fatty acids in morbidly obese individuals. Scandinavian Journal of Clinical and Laboratory Investigation, 2017, 77, 628-633.	1.2	9
48	Soluble T-Cell Immunoglobulin Mucin Domain-3 Is Associated With Hepatitis C Virus Coinfection and Low-Grade Inflammation During Chronic Human Immunodeficiency Virus Infection. Open Forum Infectious Diseases, 2020, 7, ofaa033.	0.9	9
49	Mortality and microbial diversity after allogeneic hematopoietic stem cell transplantation: secondary analysis of a randomized nutritional intervention trial. Scientific Reports, 2021, 11, 11593.	3.3	9
50	Neutrophil count predicts clinical outcome in hospitalized COVIDâ€19 patients: Results from the NORâ€Solidarity trial. Journal of Internal Medicine, 2022, 291, 241-243.	6.0	9
51	Associations of neopterin and kynurenineâ€“tryptophan ratio with survival in primary sclerosing cholangitis. Scandinavian Journal of Gastroenterology, 2021, 56, 443-452.	1.5	8
52	A Parameter for IL-10 and TGF-ÃŸ Mediated Regulation of HIV-1 Specific T Cell Activation Provides Novel Information and Relates to Progression Markers. PLoS ONE, 2014, 9, e85604.	2.5	8
53	Assessing the evidence on remdesivir. Lancet Infectious Diseases, The, 2021, 21, 1630-1631.	9.1	8
54	Reduced Trunk Fat and Triglycerides After Strength Training Are Associated With Reduced LPS Levels in HIV-Infected Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, e52-e54.	2.1	7

#	Article	IF	Citations
55	Independent Associations of Tumor Necrosis Factor-Alpha and Interleukin-1 Beta With Radiographic Emphysema in People Living With HIV. Frontiers in Immunology, 2021, 12, 668113.	4.8	7
56	Association of the Kynurenine Pathway of Tryptophan Metabolism With Human Immunodeficiency Virus-Related Gut Microbiota Alterations and Visceral Adipose Tissue Accumulation. Journal of Infectious Diseases, 2022, 225, 1948-1954.	4.0	7
57	Gut Leakage Markers in Response to Strenuous Exercise in Patients with Suspected Coronary Artery Disease. Cells, 2021, 10, 2193.	4.1	6
58	Gut related inflammation and cardiorespiratory fitness in patients with CAD and type 2 diabetes: a sub-study of a randomized controlled trial on exercise training. Diabetology and Metabolic Syndrome, 2021, 13, 36.	2.7	4
59	Alterations in the Kynurenine Pathway of Tryptophan Metabolism Are Associated With Depression in People Living With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 87, e177-e181.	2.1	4
60	Antiretroviral treatment failure predicts mortality in rural Tanzania. International Journal of STD and AIDS, 2015, 26, 633-639.	1.1	3
61	Soluble CD14 Is Associated with Markers of Vascular Dysfunction in Bariatric Surgery Patients. Metabolic Syndrome and Related Disorders, 2015, 13, 119-124.	1.3	3
62	Reply: Potential risk associated with direct modulation of the gut flora in patients with heart failure. ESC Heart Failure, 2019, 6, 557-558.	3.1	3
63	Probiotics to HIV-Infected Immunological Nonresponders: Altered Mucosal Immunity and Microbial Diversity Restricted to Ileum. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, 89, 77-86.	2.1	3
64	Plasma extracellular vesicles in people living with HIV and type 2 diabetes are related to microbial translocation and cardiovascular risk. Scientific Reports, 2021, 11, 21936.	3.3	3
65	Real-World Experiences With Facilitated Subcutaneous Immunoglobulin Substitution in Patients With Hypogammaglobulinemia, Using a Three-Step Ramp-Up Schedule. Frontiers in Immunology, 2021, 12, 670547.	4.8	1
66	No evidence of a synergistic effect of HIV infection and diabetes mellitus type 2 on fat distribution, plasma adiponectin or inflammatory markers. BMC Infectious Diseases, 2020, 20, 882.	2.9	0
67	Accelerating clinical trial implementation in the context of the COVID-19 pandemic: author's response. Clinical Microbiology and Infection, 2022, , .	6.0	0